Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 11/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.41 |
| ▸ | BCL2 | P10415 | 4/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699422 | 0.80 | PTGES (0.49) | PTGESMDM2MCL1BCL2KMT2A | |
| SCHEMBL4914621 | 0.79 | PPARG (0.47) | PTGESPPARGPPARA | |
| SCHEMBL4754926 | 0.79 | AAK1 (0.42) | PTGESPPARGMDM2MCL1BCL2 | |
| SCHEMBL4920968 | 0.79 | PPARG (0.43) | PPARGMDM2MCL1BCL2PPARA | |
| SCHEMBL4698138 | 0.78 | PTGES (0.44) | PTGESPPARGPPARA | |
| SCHEMBL4923531 | 0.78 | PPARG (0.48) | PTGESPPARGPPARA | |
| SCHEMBL6090836 | 0.76 | PPARG (0.47) | PTGESPPARGMEN1MAPTKMT2A | |
| SCHEMBL4228390 | 0.75 | PPARG (0.50) | PTGESPPARGPPARA | |
| SCHEMBL4698604 | 0.75 | PTGES (0.47) | PTGESPPARGPPARAMAPT | |
| SCHEMBL4697691 | 0.75 | PTGES (0.48) | PTGESMDM2MCL1BCL2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778633-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, PTGS1, PTGER1 | PTGES 4/4885PPARG 753/4885MDM2 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.